We ensure the standardized and high-quality implementation of Goal Attainment Scaling (GAS) in clinical trials. Through expert advisory services and structured training, along with our purpose-built GoalNav® GAS electronic Clinical Outcome Assessment (eCOA) platform, we support effective goal setting, consistent follow-up, and meaningful outcome capture.
We specialise in the design and implementation of Goal Attainment Scaling (GAS) across therapeutic areas where conventional outcome measures lack sensitivity or fail to capture the complexity and heterogeneity of patient experience.
Our expertise spans dementia, autism, oncology, and an expanding portfolio of rare and complex diseases, enabling sponsors to implement personalised endpoints that reflect clinically meaningful change at the individual level.
We offer a comprehensive suite of Goal Attainment Scaling products and services for clinical trial integration, including qualitative research for goal inventory development, study design, and quantitative and qualitative analysis. Our structured GAS site training and purpose-built GoalNav®, a GAS electronic Clinical Outcome Assessment (eCOA) platform, support consistent implementation and high-quality clinical data capture.
.webp){kind=icon}
The FDA's fourth draft guidance in the patient-focused drug development series recommends the use of personalized endpoints such as Goal Attainment Scaling (GAS) to capture meaningful change in clinical trials. We can assist in incorporating GAS research into your clinical development program.
Read guidance
.png){kind=logo}
